ABT
FDA Authorizes First Dual Glucose and Ketone Wearable, Abbott's Libre Duo
The FDA cleared the Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System for people with diabetes aged 2 and older.
ABT
Market-moving news on Abbott (NYSE: ABT): filings, earnings, deals and other events, from REDFILED.